We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Dupilumab‐induced psoriasis in the setting of pembrolizumab therapy: an analysis of cytokine expression.
- Authors
Ahmad, Maham; Murphy, Michael J.; Damsky, William; Leventhal, Jonathan
- Abstract
Cytokine RNA in situ hybridization permits individualized molecular phenotyping in biopsies of psoriasis and atopic dermatitis. We describe a unique case of dupilumab-induced psoriasis in the setting of ICPi-associated dermatitis, characterized the immunologic cytokine profiles, and successfully treated ICPi-associated psoriasis with apremilast. Immune checkpoint inhibitors (ICPis) are associated with eczematous reactions that may be treated with dupilumab in corticosteroid-resistant cases.[1] There are also mounting reports of dupilumab triggering or exacerbating psoriasis when used for presumed atopic dermatitis.[2] Here we report a case of eczematous dermatitis associated with pembrolizumab therapy successfully treated with dupilumab that was followed by the development of psoriasis and characterize the cytokine profiles of biopsy specimens before and after dupilumab.
- Subjects
GENE expression; PSORIASIS; PEMBROLIZUMAB; CYTOKINES; ECZEMA; ACNEIFORM eruptions
- Publication
International Journal of Dermatology, 2023, Vol 62, Issue 8, pe424
- ISSN
0011-9059
- Publication type
Article
- DOI
10.1111/ijd.16538